Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 6 Impact of GP88 and other clinical risk factors on overall survival.

From: Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma

Covariate Univariate GP88 adjusted for each covariate
  HR CI P- value P -value HR CI Interaction P -value
GP88 (3+ vs. < 3+) 2.45 1.53 to 3.92 0.0005 0.0002 2.45 1.54 to 3.94 -
Ethnicity (Caucasian vs. non-Caucasian) 1.29 0.74 to 2.25 0.3821 0.0003 2.41 1.50 to 3.87 0.87
Tumor size (> 2 cm vs. ≤ 2 cm) 1.66 1.22 to 2.26 0.0024 0.0012 2.21 1.3 to 3.57 0.67
Tumor size (> 5 cm vs. ≤ 5 cm) 2.18 1.08 to 4.37 0.0479     
Grade (> 1 vs. ≤ 1) 1.12 0.35 to 3.55 0.8441 0.0011 2.22 1.38 to 3.59 0.41
Grade (> 2 vs. ≤ 2) 2.11 1.30 to 3.43 0.0015     
Stage (> 1 vs. ≤ 1) 3.65 1.88 to 7.06 0.0001 0.0075 1.93 1.19 to 3.12 0.48
Stage (> 2 vs. ≤ 2) 3.59 2.19 to 5.91 < .0001     
Nodal status (Pos. vs. Neg.) 2.35 1.47 to 3.77 0.0002 0.0008 2.25 1.40 to 3.60 0.50
Age (> 50 yrs vs. ≤ 50 yrs) 1.83 1.06 to 3.15 0.0204 0.0002 2.44 1.53 to 3.90 0.37
PR (Pos. vs. Neg.) 0.92 0.55 to 1.55 0.7681 0.0001 2.71 1.63 to 4.51 0.62
Adjuvant endocrine therapy (Pos. vs. Neg.) 1.28 0.78 to 2.09 0.3205 0.0002 2.42 1.51 to 3.87 0.27
Adjuvant
chemotherapy (Pos vs. Neg.)
1.24 0.81 to 1.89 0.3255 0.0003 2.40 1.49 to 3.88 0.07
Adjuvant radiotherapy (Pos. vs. Neg.) 2.40 1.49 to 3.86 0.0008 0.007 2.00 1.21 to 3.30 0.45
  1. CPH analysis examined the impact of GP88 score and other individual clinical risk factors on OS. CI, 95% confidence interval; HR, hazard ratio. In adjusted analysis, the successive columns provide the HR of elevated GP88 adjusted for each indicator along with its P-value and 95% CI and the interaction P-value for the analysis of deviance test statistics for interaction between GP88 and that indicator.